{"id":380572,"date":"2020-11-12T21:41:14","date_gmt":"2020-11-13T02:41:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380572"},"modified":"2020-11-12T21:41:14","modified_gmt":"2020-11-13T02:41:14","slug":"shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\/","title":{"rendered":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Akers Biosciences, Inc."},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n

\n NEW YORK<\/span>, Nov. 12, 2020<\/span> \/PRNewswire\/ —\u00a0WeissLaw LLP<\/a>\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akers Biosciences, Inc. (“Akers” or the “Company”) (NASDAQ: AKER) in connection with the Company’s proposed merger with privately-held MyMD Pharmaceuticals, Inc. (“MyMD”). \u00a0Under the terms of the merger agreement, Akers and MyMD will combine resulting in current MyMD stockholders owning 80% of the newly-combined post-close company, leaving Akers stockholders with a mere 20% of the new entity.\u00a0 Additionally, the merger agreement also provides for cash and stock payments to MyMD stockholders under certain circumstances. \u00a0The combined company will continue to trade on the NASDAQ under the new ticker symbol “MYMD.”\u00a0 <\/p>\n

\n

\n
\n \"WeissLaw
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n
\n If you own Akers shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:<\/u>
\n <\/b>\n <\/p>\n

\n
\n http:\/\/www.weisslawllp.com\/aker\/<\/a>
\n <\/b>\n <\/p>\n

\n
\n Or please contact:
<\/u>
\n <\/b>
\n
\n Joshua Rubin, Esq.<\/span>
\n
\n <\/b>WeissLaw LLP
1500 Broadway, 16th<\/sup> Floor
New York<\/span>, NY\u00a0 10036
(212)\u00a0682-3025
<\/b>(888) 593-4771
stockinfo@weisslawllp.com<\/a><\/b><\/p>\n

WeissLaw is investigating (i) whether Akers’ board acted in the best interest of Akers’ public stockholders in agreeing to the proposed transaction, (ii) whether the board was fully informed as to the value of privately-held MyMD, (iii) whether the deal’s equity split is fair to Akers’ stockholders, and (iv) whether all information regarding the sales process undertaken by the board and financial analyses supporting the transaction will be fully and fairly disclosed to Akers’ public stockholders.\u00a0 <\/p>\n

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.\u00a0 We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.\u00a0 If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com<\/a><\/b><\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc-301172500.html<\/a><\/p>\n

SOURCE WeissLaw LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK, Nov. 12, 2020 \/PRNewswire\/ —\u00a0WeissLaw LLP\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akers Biosciences, Inc. (“Akers” or the “Company”) (NASDAQ: AKER) in connection with the Company’s proposed merger with privately-held MyMD Pharmaceuticals, Inc. (“MyMD”). \u00a0Under the terms of the merger agreement, Akers and MyMD will combine resulting in current MyMD stockholders owning 80% of the newly-combined post-close company, leaving Akers stockholders with a mere 20% of the new entity.\u00a0 Additionally, the merger agreement also provides for cash and stock payments to MyMD stockholders under certain circumstances. \u00a0The combined company will continue to trade on the NASDAQ under the new ticker symbol “MYMD.”\u00a0 If you own … <\/p>\n

Continue reading “SHAREHOLDER ALERT: WeissLaw LLP Investigates Akers Biosciences, Inc.”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-380572","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSHAREHOLDER ALERT: WeissLaw LLP Investigates Akers Biosciences, Inc. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Akers Biosciences, Inc. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Nov. 12, 2020 \/PRNewswire\/ —\u00a0WeissLaw LLP\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akers Biosciences, Inc. (“Akers” or the “Company”) (NASDAQ: AKER) in connection with the Company’s proposed merger with privately-held MyMD Pharmaceuticals, Inc. (“MyMD”). \u00a0Under the terms of the merger agreement, Akers and MyMD will combine resulting in current MyMD stockholders owning 80% of the newly-combined post-close company, leaving Akers stockholders with a mere 20% of the new entity.\u00a0 Additionally, the merger agreement also provides for cash and stock payments to MyMD stockholders under certain circumstances. \u00a0The combined company will continue to trade on the NASDAQ under the new ticker symbol “MYMD.”\u00a0 If you own … Continue reading "SHAREHOLDER ALERT: WeissLaw LLP Investigates Akers Biosciences, Inc."\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-13T02:41:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Akers Biosciences, Inc.\",\"datePublished\":\"2020-11-13T02:41:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\\\/\"},\"wordCount\":352,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\\\/\",\"name\":\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Akers Biosciences, Inc. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\",\"datePublished\":\"2020-11-13T02:41:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/743985\\\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER ALERT: WeissLaw LLP Investigates Akers Biosciences, Inc.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Akers Biosciences, Inc. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Akers Biosciences, Inc. - Market Newsdesk","og_description":"PR Newswire NEW YORK, Nov. 12, 2020 \/PRNewswire\/ —\u00a0WeissLaw LLP\u00a0is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akers Biosciences, Inc. (“Akers” or the “Company”) (NASDAQ: AKER) in connection with the Company’s proposed merger with privately-held MyMD Pharmaceuticals, Inc. (“MyMD”). \u00a0Under the terms of the merger agreement, Akers and MyMD will combine resulting in current MyMD stockholders owning 80% of the newly-combined post-close company, leaving Akers stockholders with a mere 20% of the new entity.\u00a0 Additionally, the merger agreement also provides for cash and stock payments to MyMD stockholders under certain circumstances. \u00a0The combined company will continue to trade on the NASDAQ under the new ticker symbol “MYMD.”\u00a0 If you own … Continue reading \"SHAREHOLDER ALERT: WeissLaw LLP Investigates Akers Biosciences, Inc.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-13T02:41:14+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Akers Biosciences, Inc.","datePublished":"2020-11-13T02:41:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\/"},"wordCount":352,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\/","name":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Akers Biosciences, Inc. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","datePublished":"2020-11-13T02:41:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/743985\/WeissLaw_Logo_Stacked_LowerCase_color_2_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-weisslaw-llp-investigates-akers-biosciences-inc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER ALERT: WeissLaw LLP Investigates Akers Biosciences, Inc."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=380572"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380572\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=380572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=380572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=380572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}